ZWZhijiang Wei

Zhijiang Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhijiang Wei has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Guiying Liu

    The First Department of Surgical Oncology, Cangzhou Central Hospital, Cangzhou, China

    1 shared publication
  • Li Li

    The Brain Science Unit, CangZhou Central Hospital, Cangzhou, China

    1 shared publication
  • Rufu Jia

    The Brain Science Unit, CangZhou Central Hospital, Cangzhou, China

    1 shared publication
  • Wei Zhang

    The First Department of Surgical Oncology, Cangzhou Central Hospital, Cangzhou, China

    1 shared publication
  • Xiyong Bai

    The First Department of Surgical Oncology, Cangzhou Central Hospital, Cangzhou, China

    1 shared publication
  • Yuanyuan Zhang

    The First Department of Surgical Oncology, Cangzhou Central Hospital, Cangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Targeting secretory leukocyte protease inhibitor (SLPI) inhibits colorectal cancer cell growth, migration and invasion via downregulation of AKT

    by Zhijiang Wei, Guiying Liu, Rufu Jia, Wei Zhang, Li Li, Yuanyuan Zhang, Zhijing Wang, Xiyong Bai

    The secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor which plays important role in bacterial infection, inflammation, wound healing and epithelial proliferation. Dysregulation of SLPI has been reported in a variety of human cancers including glioblastoma, lung, breast, ovarian and colorectal carcinomas and is associated with tumor aggressiveness and metastatic potential. However, the pathogenic role of SLPI in colorectal cancer is still unclear. Here we showed that SLPI mRNA level was significantly upregulated in colorectal cancer tissues compared to adjacent normal controls. Targeting SLPI by siRNA inhibited proliferation, migration and invasion of colorectal cancer cells lines HT29 and HT116 in vitro. Mechanistically, blockage of cancer cell growth and metastasis after SLPI knockdown was associated with down-regulation of AKT signaling. In conclusion, SLPI regulated colorectal cell growth and metastasis via AKT signaling. SLPI may be a novel biomarker and therapeutic target for colorectal cancer. Targeting AKT signaling may be effective for colorectal cancer treatment.